Sign up Australia
Proactive Investors - Run By Investors For Investors

Admedus has capital raising news imminent, granted ASX trading halt

The halt will remain in place until the start of trade on August 6 or earlier if an announcement is released.
ASX sign
Admedus’ medical technologies are aimed at creating life-changing outcomes

Admedus Ltd (ASX:AHZ) has been granted a trading halt by the ASX pending news of a capital raising.

The halt will remain in place until the start of trade on ASX on Monday, August 6, or earlier if an announcement is released to the market.

Shares last traded at 13.5 cents before the halt.

READ: Admedus commences animal trials for heart valve device

During July the company released news regarding progress with its patented transcatheter aortic valve replacement (TAVR) project and its ADAPT® technology.

Admedus has commenced animal trials by completing the first successful live implantation of its unique single-piece aortic heart valve, representing a key milestone in development of the TAVR project.

Five-month trial

The company has partnered with a European lab to examine the safety and feasibility of the unique valve in live sheep.

Implanting of the first single-piece valve officially marked the start of the trial period, which is expected to last for around five months.

READ: Admedus signs exclusive distribution agreement in Italy for its unique heart tissue product

Earlier in July, the company signed an exclusive distribution agreement with Medical Instruments S.p.A. to market and distribute its clinically-superior ADAPT® technology in Italy.

Under the agreement, Medical Instruments will initially distribute Admedus’ non-toxic and non-calcifying flagship ADAPT bio-scaffold CardioCel®.

The bio-scaffold is used to repair congenital heart deformities and more complex heart defects.

It is also used to reconstruct dysfunctional heart valves and valve leaflets.

View full AHZ profile View Profile

Admedus Ltd Timeline

Related Articles

surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
August 21 2018
The company aims to revolutionise the HPA production process, eschewing the laborious bauxite-sourced method.
September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use